Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DHR - DANAHER CORP /DE/


Close
231.08
-0.520   -0.225%

Share volume: 64,732
Last Updated: Fri 27 Dec 2024 08:30:05 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 0.90%

PREVIOUS CLOSE
CHG
CHG%

$231.60
-0.52
-0.22%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
44%
Profitability 34%
Dept financing 37%
Liquidity 75%
Performance 48%
Company vs Stock growth
vs
Performance
5 Days
0.93%
1 Month
-3.16%
3 Months
-16.03%
6 Months
-8.13%
1 Year
-0.68%
2 Year
-11.35%
Key data
Stock price
$231.08
P/E Ratio 
46.28
DAY RANGE
$229.90 - $232.07
EPS 
$6.02
52 WEEK RANGE
$227.49 - $281.70
52 WEEK CHANGE
-$0.03
MARKET CAP 
194.499 B
YIELD 
0.39%
SHARES OUTSTANDING 
722.213 M
DIVIDEND
$0.27
EX-DIVIDEND DATE
06/28/2024
NEXT EARNINGS DATE
10/29/2024
BETA 
0.79
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$3,622,831
AVERAGE 30 VOLUME 
$3,367,957
Company detail
CEO: Rainer M. Blair
Region: US
Website: danaher.com
Employees: 81,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics.

Recent news